ADHD Genes Found; Known to Play Roles in Neurodevelopment

... variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD. Many of those genes were ... Elia et al, "Rare Structural Variants Found in Attention-Deficit hyperactivity Disorder Are Preferentially Associated with Neurodevelopmental Genes," ...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

... found once-daily VYVANSE significantly improved Attention Deficit hyperactivity Disorder (ADHD) symptoms in adults within the first week of treatment. ... symptoms of inattention, such as the ability to focus and organize, and hyperactivity and impulsivity, such as restlessness, and interrupting." VYVANSE ...

New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months

... and finish tasks), while boys tend to exhibit disruptive symptoms such as hyperactivity and impulsivity (e.g., restlessness, interrupting, impulsive decisions). ... market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not ...

Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose

... is being evaluated for the treatment of the symptoms of Attention Deficit hyperactivity Disorder (ADHD). The data demonstrated that INTUNIV showed significant ... market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not ...

Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration

... the first prodrug stimulant for the treatment of Attention Deficit hyperactivity Disorder (ADHD), provided significant efficacy in children for up to 12 ... market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not ...

Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting

... the phase III pivotal study in pediatric patients with Attention Deficit hyperactivity Disorder (ADHD) showed the effect size of VYVANSE was 1.39, 1.42 and 1.73 ... and establishment in the market of VYVANSE(TM) (Attention Deficit and hyperactivity Disorder ("ADHD"); the impact of competitive products including, but not ...

Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)

... DAYTRANA(TM) (methylphenidate transdermal system), the Attention Deficit hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ... but not limited to the impact of those on Shire's Attention Deficit and hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal ...

Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting

... results of a study which demonstrated that adults with Attention Deficit hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom ... but not limited to the impact of those on Shire's Attention Deficit and hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal ...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent ...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

... specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent ...

Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms

... specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent ...

Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy

... functions such as stress, pain, sleep and blood pressure. Addrenex's lead products are Clonicel(R) for the treatment of attention-deficit hyperactivity disorder (ADHD) and Sympres(R) for the treatment of hypertension. The company also plans to develop drugs to treat menopausal flushing and ...

Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

... demonstrating that the combination of Clonicel with stimulant medications provided statistically significant improvements in attention deficit hyperactivity disorder (ADHD) symptoms compared to stimulant use alone. Clonicel is the company's lead compound in a pipeline of products that have shown ...

Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)

... the European Marketing Authorization Application (MAA) for DAYTRANA(TM) (methylphenidate transdermal system) for the treatment of Attention Deficit hyperactivity Disorder (ADHD). A request from European regulators to conduct an additional clinical study on DAYTRANA in a European patient population combined ...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

... biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent ...

Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD

... company, today announced results from a 13-hour analog classroom study in school-aged children aged 6 to 12 years with Attention Deficit hyperactivity Disorder (ADHD). In this study, researchers found that VYVANSE controlled ADHD symptoms from the first time point measured (1.5 hours) through the ...

Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415

... the unmet needs of patients across a wide range of conditions." The company's first two drug candidates are Clonicel to treat attention deficit hyperactivity disorder (ADHD) and CloniBID to treat hypertension. Clonicel is currently in phase 3 trials, and a new drug application has been filed for CloniBID ...

Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD

... 10 /PRNewswire/ -- A drug that diminishes the body's hyper-reactivity to stress has been shown to significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in children, according to a phase 3 clinical trial conducted by Addrenex Pharmaceuticals. The study showed that the new drug, ...

Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day

... Deficit/Hyperactivity Disorder affects approximately three to seven percent of children in the United States, and its symptoms -- inattention, hyperactivity and impulsivity -- can significantly impact a child's ability to focus and learn in an educational setting. The study included children between the ...

Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent

... commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, ...

Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil

... commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, ...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

... commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, ...

Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists

... commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, ...

Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting

... commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, ...

Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy

... commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, ...

Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients

... commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, ...

Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

... suggest that these compounds may have utility in treating disorders, as widely diverse as cognitive dysfunction in schizophrenia, attention deficit hyperactivity disorder and the cognitive deficits arising from Parkinson's and Alzheimer's diseases. ITI-002 also may be useful in treating the motor deficits that ...

New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo

... was well tolerated in an adult population with ADHD in a dose range from 36mg to 108 mg per day for up to six months. About ADHD Attention Deficit hyperactivity Disorder (ADHD) is a common and treatable neuropsychiatric condition, which includes inattention, hyperactivity and impulsivity. According to the ...

Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation

... increasing chances of creating potentially lethal blood clots causing heart attack and stroke. "By identifying mechanisms responsible for the hyperactivity of platelets during hyperlipidemia, new therapies may be developed to prevent inappropriate platelet activation and reduce the risk of ...

Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD

... -- The results of a pilot study published in the Nutrition Journal (http://www.nutritionj.com ) suggest that children with attention deficit hyperactivity disorder (ADHD) can benefit from daily supplementation of high levels of purified fish oils. The eight-week study demonstrated that children who ...

New Data Suggests Less Abuse-Related Effects For OROS Methylphenidate

... prescribe medications to treat Attention Deficit hyperactivity Disorder (ADHD). Data presented on Tuesday at the ... IR MPH doses (P About ADHD Attention Deficit hyperactivity Disorder (ADHD) is a common and treatable medical ... which includes a variable attention span and/or hyperactivity or impulsivity. According to the ...

New Data Focuses on Abuse of Stimulant Medication

... prescribe medications to treat Attention Deficit hyperactivity Disorder (ADHD). Data presented on Tuesday at the ... was mg 108 (P About ADHD Attention Deficit hyperactivity Disorder (ADHD) is a common and treatable medical ... which includes a variable attention span and/or hyperactivity or impulsivity. According to the ...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

... physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and ... but not limited to the impact of those on Shire's Attention Deficit and hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, ...

Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation

... bipolar disorder and dementia, characterized by an unpleasant degree of arousal, tension and irritability, frequently leading to confusion, hyperactivity and hostility. According to the National Institute of Mental Health, schizophrenia afflicts more than three million people in the United States. ...

Study Shows Children With ADHD Who Start on Strattera are More Likely to Change Therapies

... Prime Therapeutics (Prime) today announced the results of a study on the utilization of Strattera(R) (atomoxetine) for treating attention deficit hyperactivity disorder (ADHD) in children. The study found that children who start on Strattera were 4.2 times more likely to change their therapy than children ...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

... company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to ...

BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference

... dopamine blockade by dose dependant elevation in serum prolactin levels which serves as a surrogate marker for dopamine antagonism. Dopamine hyperactivity is implicated in schizophrenia, and is the mechanism of action for various antipsychotic drugs. 2. In this trial BL-1020 appeared to be protective ...

12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)

... that DAYTRANA(TM) (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a ...

Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls

... DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc announced today that DAYTRANA(TM) (methylphenidate transdermal system), its Attention Deficit hyperactivity Disorder (ADHD) patch, had significant efficacy in reducing the symptoms of ADHD in both male and female children aged 6 to 12 years, according to ...